STRO Stock — Sutro Biopharma

Sutro Biopharma (STRO)

Updated October 16, 2026.

STRO is a Stock. Total return is -92.8% over the past 8.1 years, 288.8 points behind SPY at 196.0%.

Sutro Biopharma is an oncology company developing antibody drug conjugates (ADCs) and vaccine candidates using proprietary protein synthesis and site-specific conjugation platforms. Its pipeline includes lead programs targeting tissue factor and ROR1 for various solid tumors and hematological cancers, along with pneumococcal vaccine candidates in clinical trials, supported by partnerships with companies including Ipsen and Astellas. The company does not currently have an established distribution schedule.

STRO performance versus SPY

Price and return data through 2026-10-16.

Total return is -92.8% over the past 8.1 years, 288.8 points behind SPY at 196.0%. Over the past year its total return — price change plus distributions reinvested — is 24.2%. Its deepest 1-year drawdown was 74.3%.

STRO key facts

Asset type

Stock

Asset class

Equity

Inception date

09/27/2018

Distribution frequency

None

Last close

$10.94 (as of 2026-10-16)

Market cap

$181,398,011

Average volume

363464.0

Beta

1.491

Payout ratio

0.0%

Forward P/E

10.0301

EPS

$-17.37

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

STRO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 74.3%.

Who may consider STRO — and who may not

It is a weaker fit for investors who need monthly cash flow (STRO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on STRO

• All tickers starting with S

Tagged: Healthcare.

Frequently asked questions